Core Thesis - Alphatec Holdings, Inc. (ATEC) presents a bearish investment thesis due to structural headwinds and material downside risks over the next 12 months, particularly following its 4Q'25 results [3][6] Company Overview - ATEC is a medical technology company focused on surgical treatments for spinal disorders, operating both in the United States and internationally [3] Market Dynamics - The company's flagship Prone TransPsoas (PTP) approach to lumbar fusion only addresses a subset of the spinal surgery market, with approximately 19% of fusion-eligible patients unable to use PTP and another 25-33% for whom it is non-ideal [3] - A significant portion of the target population, particularly those with spinal stenosis or herniated discs, either do not require fusion or are better served with decompression procedures, reducing the effective total addressable market to roughly $6 billion, which is about 42% below bullish estimates [4] Regulatory Environment - Regulatory pressures, such as CMS's WISER AI-driven pre-authorization for outpatient fusions, further constrain volumes, especially as outpatient procedures have increased from 2% to 26% of the market [4] Competitive Landscape - Competitor products have achieved technological parity, with ATEC lagging in surgical robotics and overall device functionality, which undermines its previous competitive advantage and limits future case growth [5] - The newly launched Valence robot is considered less capable than offerings from competitors like Medtronic, Globus, and Vista, leading to expectations of slow adoption [5] Financial Outlook - Recent growth in ATEC's sales was largely driven by elevated sales commissions, which are now being normalized, suggesting potential sales rep churn in FY'26 that could threaten surgical volume and market share [5] - Valuation multiples are expected to compress as ATEC faces decelerating sales growth, pricing pressure, and shrinking market opportunities, with a base-case target price of $14.2 indicating approximately 33% downside from current levels [6] - The company is viewed as a high-conviction short with substantial downside potential relative to its current market price [6]

Core Thesis - Alphatec Holdings, Inc. (ATEC) presents a bearish investment case due to structural headwinds and material downside risks over the next 12 months, particularly following its 4Q'25 results [3][6] Company Overview - ATEC is a medical technology company focused on surgical treatments for spinal disorders, operating both in the United States and internationally [3] Market Limitations - The flagship Prone TransPsoas (PTP) approach addresses only a subset of the spinal surgery market, with approximately 19% of fusion-eligible patients unable to use PTP and another 25-33% for whom it is non-ideal [3] - A significant portion of the target population, particularly those with spinal stenosis or herniated discs, either do not require fusion or are better served with decompression procedures, reducing the effective total addressable market to roughly $6 billion, which is about 42% below bullish estimates [4] Regulatory Challenges - Regulatory pressures, such as CMS's WISER AI-driven pre-authorization for outpatient fusions, further constrain volumes, especially as outpatient procedures have increased from 2% to 26% of the market [4] Competitive Landscape - Competitor products have achieved technological parity, with ATEC lagging in surgical robotics and overall device functionality, undermining its previous competitive advantage and limiting future growth [5] - The newly launched Valence robot is considered less capable than offerings from competitors like Medtronic, Globus, and Vista, leading to expectations of slow adoption [5] Sales and Growth Concerns - Recent growth was primarily driven by elevated sales commissions, which are now being normalized, indicating potential sales rep churn in FY'26 that could threaten surgical volume and market share [5] - Valuation multiples are expected to compress as ATEC faces decelerating sales growth, pricing pressure, and shrinking market opportunities, with a base-case target price of $14.2 implying approximately 33% downside from current levels [6]

Core Insights - Stereotaxis reported a revenue growth of over 20% for the year 2025, driven by significant regulatory approvals and advancements in their product pipeline [2][4] - The company achieved regulatory approvals for key products including the GenesisX robot and MAGiC catheters, which are expected to drive future commercial growth [3][4] Financial Performance - Fourth quarter revenue for 2025 was $8.6 million, a 36% increase from $6.3 million in Q4 2024 [4] - Full year revenue for 2025 totaled $32.4 million, representing a 20% increase from $26.9 million in 2024 [4] - System revenue for the full year grew 18% to $10.2 million, while recurring revenue increased by 21% to $22.2 million [4] Gross Margins and Expenses - Gross margin for Q4 2025 was approximately 50%, while the full year gross margin was about 53% [5] - Operating expenses for Q4 2025 were $10.0 million, with adjusted operating expenses at $7.0 million after excluding non-cash charges [5] Losses - The operating loss for Q4 2025 was ($5.6) million, an improvement from ($7.6) million in Q4 2024 [6] - For the full year 2025, the adjusted operating loss was ($9.3) million, compared to ($12.4) million in 2024 [7] Cash Position - As of December 31, 2025, Stereotaxis had cash and cash equivalents of $13.4 million and no debt [8] - The company raised $3.1 million through an at-the-market offering during Q4 2025 [8] Future Outlook - Stereotaxis anticipates double-digit revenue growth for 2026, expecting annual revenue to surpass $40 million [9] - The company aims to achieve four key milestones in 2026 to support future growth [6][9]

Core Insights - Intuitive Surgical has a strong market presence with over 11,100 da Vinci surgical robots installed globally, generating approximately 75% of its revenue from services and sales of instruments and accessories, creating a recurring revenue stream [2] - The company currently has a high price-to-earnings (P/E) ratio of 64, indicating strong market expectations for future growth [1] - Medtronic has recently received FDA approval for its Hugo surgical robot, marking its entry into the U.S. market, with the first surgeries performed in February [4] Company Analysis - Intuitive Surgical's da Vinci system has established a significant foothold in the surgical robotics market, but competition is increasing, with Medtronic emerging as a notable player [4] - Medtronic's P/E ratio stands at 27, which is lower than that of Intuitive Surgical, suggesting potential for valuation growth if the Hugo system achieves similar success as the da Vinci system [5] - Medtronic's business is more diversified across various medical sectors, which may limit the growth potential of the Hugo system compared to Intuitive Surgical's focused approach [7] Investment Considerations - Medtronic offers a dividend yield of approximately 2.9%, appealing to dividend investors, while Intuitive Surgical does not provide dividends [8] - The market is currently in a cautious phase regarding Medtronic's new product developments, but the introduction of the Hugo system could change investor sentiment [7]

Group 1: Intuitive Surgical Overview - Intuitive Surgical is a leader in surgical robotics, primarily due to its da Vinci surgical systems, with 11,106 systems installed by the end of 2025, reflecting a 12% year-over-year increase [2] - The number of surgeries performed using da Vinci systems increased by 18% year-over-year, indicating strong demand for the company's robots [2] - Approximately 25% of Intuitive Surgical's revenue comes from new robot sales, while the majority is generated from parts and services, creating a stable income stream that grows with each new system sold [5] Group 2: Competitive Landscape - Medtronic, a competitor in the medical device sector, has a P/E ratio of 26, making it a more attractively valued option compared to Intuitive Surgical's P/E ratio of 64 [1][6] - Medtronic is developing its own surgical robot, Hugo, which is not as advanced as the da Vinci system but is progressing and presents a significant growth opportunity [6][7] - Medtronic's diversified portfolio as one of the largest medical device companies supports its entry into surgical robotics, and the FDA approved Hugo for use in the U.S. in late 2025 [7] Group 3: Investment Considerations - Medtronic offers a dividend yield of 2.9% and is approaching Dividend King status, with a history of annual dividend increases nearing 50 years [8] - A $10,000 investment in Medtronic could yield around 100 shares, and as the Hugo system's installed base expands over the next decade, the stock may see a higher valuation, providing both income and growth potential [9]

Core Insights - Microbot Medical Inc. announced that CEO Harel Gadot will participate as a panelist at The Surgical Disruptive Technology Summit, part of SAGES NBT Innovation Weekend, from February 19-21, 2026, in Houston, TX [1] - The summit aims to foster dialogue between industry and providers on innovations in surgical technology, focusing on minimally invasive interventions [2] Company Overview - Microbot Medical is a commercial stage medical device company dedicated to transforming endovascular procedures through advanced robotic technology [4] - The LIBERTY® Endovascular Robotic System is the first FDA cleared, single-use, remotely operated robotic solution designed for precision, efficiency, and safety in peripheral endovascular procedures [4] Product Features and Market Strategy - The LIBERTY System is designed to enhance access, safety, and clinical outcomes in vascular care, featuring remote interventions and precision navigation [2] - The company commenced limited market release of the LIBERTY system in late 2025 and plans a full market release at the Society of Interventional Radiology (SIR) conference in April 2026 [3] - LIBERTY's single-use, compact design aims to eliminate barriers to broader adoption of surgical robotics, positioning it as a new class of surgical robotics [3]

Core Insights - Intuitive Surgical's stock is currently considered expensive with a P/E ratio of 60, compared to the S&P 500 average of 28, but presents a potential opportunity for long-term growth investors following a recent price drop [2][6] - The company manufactures the da Vinci surgical robot, which has seen a 12% year-over-year increase in operational systems and an 18% rise in surgeries performed, indicating strong demand in the market [3] - Only 25% of the company's revenue comes from robot sales, with the majority derived from services, instruments, and accessories, creating a recurring income stream that grows with each new robot sold [5] Financial Performance - The stock has experienced significant volatility, with frequent drawdowns of 25% to 30%, suggesting potential buying opportunities for long-term investors [7] - The current P/E ratio of 60 is below its five-year average of 71, indicating a relative decrease in valuation due to the January drawdown [6] - The stock is approximately 19% below its 2026 high and 21% below its all-time high reached in late 2025, highlighting potential for recovery [6] Market Position - Intuitive Surgical is well-positioned in the healthcare sector, benefiting from advancements in AI and improved surgical outcomes through robotic assistance, which may enhance its long-term growth prospects [5] - The company’s market capitalization stands at $173 billion, with a gross margin of 65.99%, reflecting strong profitability [7]

As filed with the Securities and Exchange Commission on February 2, 2026 Registration No. 333- SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SS INNOVATIONS INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Florida 3841 47-3478854 (I.R.S. Employer Identification No.) 405, 3 Floor, iLabs Info Technology Centre Udyog Vi ...

Company Overview - PROCEPT BioRobotics is a healthcare technology company specializing in robotic surgical systems for minimally invasive urology procedures, particularly targeting benign prostatic hyperplasia (BPH) treatment [6][9] - The company utilizes proprietary image-guided robotic systems to enhance patient outcomes and hospital efficiency, with a competitive edge stemming from its innovative Aquablation therapy and a growing installed base [6][9] Financial Performance - As of January 26, PROCEPT BioRobotics had a market capitalization of $1.65 billion, with a trailing twelve months (TTM) revenue of $299.91 million and a net income loss of $84.58 million [4] - The company reported a 43% year-over-year revenue increase in the third quarter, amounting to $83.3 million, and a gross margin expansion to 65% [11] - Management provided revenue guidance for 2026, projecting between $410 million and $430 million, indicating potential growth of up to 32% from 2025 levels [11] Recent Transactions - Chicago Capital disclosed a reduction in its stake in PROCEPT BioRobotics by 377,850 shares in the fourth quarter, translating to an estimated transaction value of $12.53 million [2][3] - Following this transaction, Chicago Capital's remaining stake in PROCEPT was valued at $37.47 million, with the position now accounting for 0.93% of its 13F assets, down from 1.38% in the previous quarter [2][3] Stock Performance - As of January 26, PROCEPT BioRobotics shares were priced at $29.61, reflecting a significant decline of 60.4% over the past year, contrasting sharply with the S&P 500's approximate 14% gain during the same period [3][11] - The stock's performance has raised concerns regarding operating losses, high spending, and the pace at which growth can lead to sustainable profitability, as evidenced by an adjusted EBITDA loss of $7.4 million in the quarter [11]

Core Viewpoint - SS Innovations International, Inc. anticipates strong revenue growth driven by increased unit sales of its SSi Mantra surgical robotic system, with significant growth expected in both the fourth quarter and full year of 2025 [1][3]. Financial Performance - For the fourth quarter of 2025, the company expects revenue of approximately $15.0 million, representing an 85% increase from $8.1 million in the fourth quarter of 2024 [7]. - For the full year 2025, the company expects revenue of approximately $43.0 million, which is a 108% increase from $20.6 million in 2024 [7]. - The cumulative installed base of the SSi Mantra reached 168 units as of December 31, 2025, marking a 158% increase from 65 units as of December 31, 2024 [2]. Product Development and Market Expansion - The SSi Mantra surgical robotic system is designed to be cost-effective and user-friendly, with advanced features such as modular robotic arms and a 3D 4K monitor [6]. - The company is committed to expanding its market presence in India, the United States, and Europe, with expectations for FDA review and EU CE marking certification in the first half of 2026 [3].